Weekly Digest – April 2025 Weekly Digest – April 2025 24 Apr 2025: ENHERTU supplemental New Drug Application submitted in Japan for patients with HER2 positive metastatic Solid tumors Daiichi Sankyo has submitted a supplemental New Drug Application in Japan […]
Weekly Digest – April 2025 Weekly Digest – April 2025 21 Apr 2025: Sichuan Kelun-Biotech’s SKB518 receives FDA clearance for clinical trials Kelun-Biotech has received IND clearance from the U.S. FDA to begin clinical trials for its novel antibody-drug conjugate […]
Weekly Digest – April 2025 Weekly Digest – April 2025 21 Apr 2025: Enhertu plus Pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2-positive metastatic Breast cancer The […]
Weekly Digest – April 2025 Weekly Digest – April 2025 21 Apr 2025: Gilead Sciences reports positive data From Phase 3 ASCENT-04/KEYNOTE-D19 study The Phase 3 ASCENT-04 trial showed that Trodelvy combined with Keytruda significantly improved progression-free survival compared to […]
Weekly Digest – April 2025 Weekly Digest – April 2025 22 Apr 2025: Synthetic Design Lab emerges with $20M to advance next-generation ADCs Synthetic Design Lab launched with $20 million in seed funding to develop next-generation antibody-drug conjugates (ADCs) using […]
Weekly Digest – April 2025 Weekly Digest – April 2025 22 Apr 2025: 1st Biotherapeutics and Ligachem Biosciences partner on ADC payloads and immuno-oncology candidates 1st Biotherapeutics and LigaChem Biosciences have formed a strategic R&D and licensing option agreement to […]
